On May 13, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care reported the addition of Penn Medicine’s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell’s ongoing pivotal Phase 3 clinical study (Bria-ABC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine’sarticle, " Eleven clinical trials that will shape medicine in 2026". The Phase 3 Bria-ABC study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in advanced breast cancer.
"We are pleased to partner with Penn Medicine’s Abramson Cancer Center, a world-renowned cancer institute, as a clinical site in BriaCell’s Phase 3 study," stated Dr. William V. Williams, BriaCell’s President & CEO. "We look forward to working with the cancer experts at Penn to offer the Bria-IMT regimen to patients with metastatic breast cancer with the goal of making a meaningful difference for patients who have not responded to prior therapies."
"The addition of Penn Medicine’s Abramson Cancer Center supports our goal of expanding access to BriaCell’s novel immunotherapy regimen to patients with metastatic breast cancer across the greater Philadelphia region," said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer.
Other recently activated sites include:
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN
University of Virginia (UVA) Comprehensive Cancer Center, Charlottesville, VA
Baptist Health South Florida, Coral Gables, FL
SCRI Oncology Partners, Nashville, TN
An interim analysis of the pivotal Phase 3 study will be conducted after 144 patient events, defined as deaths, have occurred. Overall survival (OS) is the primary endpoint. The study compares the Bria-IMT regimen in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in patients with advanced metastatic breast cancer. The Bria-IMT combination regimen has received FDA Fast Track designation, reflecting its potential to address a serious unmet medical need.
For additional information on BriaCell’s pivotal Phase 3 study, please visit ClinicalTrials.gov NCT06072612.
(Press release, BriaCell Therapeutics, MAY 13, 2026, View Source [SID1234666090])